Medpace (NASDAQ:MEDP) Stock: Insider August Troendle Sells 26,701 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 26,701 shares of Medpace stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $621.02, for a total transaction of $16,581,855.02. Following the sale, the chief executive officer owned 360,191 shares in the company, valued at approximately $223,685,814.82. This represents a 6.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Medpace Stock Performance

Shares of NASDAQ MEDP traded down $26.10 during trading on Thursday, hitting $598.08. The company had a trading volume of 232,765 shares, compared to its average volume of 330,847. The company has a market cap of $16.69 billion, a P/E ratio of 35.06, a PEG ratio of 2.78 and a beta of 1.15. The business’s 50-day moving average is $600.14 and its 200 day moving average is $519.59. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on MEDP shares. Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Truist Financial lifted their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Mizuho boosted their price target on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Finally, Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average price target of $602.27.

Institutional Investors Weigh In On Medpace

Several large investors have recently bought and sold shares of MEDP. Johnson Financial Group Inc. bought a new stake in shares of Medpace in the 2nd quarter valued at $27,000. Jones Financial Companies Lllp acquired a new position in Medpace during the 2nd quarter worth approximately $30,000. Allied Private Wealth LLC bought a new position in Medpace in the second quarter valued at $31,000. Kilter Group LLC bought a new position in shares of Medpace in the 2nd quarter valued at about $31,000. Finally, Basecamp Wealth Advisors LLC grew its stake in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.